Drug manufacturer Lilly’s announcement last week that it is slashing the price of Humalog, its most commonly prescribed insulin, may have been less about altruism and more about avoiding exposure to bigger Medicaid rebates, a prominent drug pricing expert says.
…
Generic drug manufacturer Zydus Pharmaceuticals USA said in a recent public notice it will pay refunds for 340B overcharges that occurred mostly in the first two quarters of 2022. The products include Zydus’ equivalents of the widely prescribed antibiotic Zithromax,
…
The 340B program—and whether it needs change, protection, or both—came up often today during a U.S. Senate hearing on federal funding of community health centers.
The bulk of health centers’ federal grant funding—about $5.8 billion annually from the U.S. Health
…
Associations representing community health centers and brand drug manufacturers are jointly developing 340B policy proposals for Congress to consider, hospital group 340B Health told its members yesterday.
The National Association of Community Health Centers said yesterday that it had no
…
UPDATED Thursday March 2, 2023, 12:30 p.m. EDT to include comment from HRSA.
The U.S. Health Resources and Services Administration has asked multiple hospitals to explain how they determine patient eligibility for 340B drugs, how they define, track, and use
…
The federal government may ask all 14 judges on the U.S. Third Circuit Court of Appeals to review a three-judge panel’s unanimous January opinion upholding AstraZeneca, Novo Nordisk, and Sanofi’s restrictions on 340B pricing when their drugs are shipped to
…
The 340B program “is a really successful program and it hasn’t really cut the profits of the pharmaceutical companies dramatically,” U.S. Senate Majority Whip Dick Durbin (D-Ill.) said Friday during a visit to a Chicago-based community health center.
Durbin is
…
Pharmaceutical Research and Manufacturers of America asked a U.S. appeals court in St. Louis, Mo. last week to strike down Arkansas’s first-of-its-kind 340B contract pharmacy law, arguing that it intrudes on the 340B statute and frustrates Congress’ intent to limit
…
A federal district judge in Baltimore, Md., yesterday stayed the brand drug industry’s lawsuit challenging the December 2020 340B program administrative dispute resolution final rule.
Lawyers for Pharmaceutical Research and Manufacturers of America and U.S. Health and Human Services Secretary
…
Could ending the fights over limits on 340B contract pharmacy and encroachment on providers’ 340B savings hinge on hospitals accepting 340B reporting requirements? 340B Report Publisher and CEO Ted Slafsky raises that provocative question in his monthly column for Verity
…*Sign up for news summaries and alerts from 340B Report